美罗培南药动学/药效学及特殊人群用药的研究进展

徐红艳; 黄健; 武阿龙; 徐丙发

doi:10.6039/j.issn.1001-0408.2023.13.23

您当前的位置：

首页 >

文章列表页 >

美罗培南药动学/药效学及特殊人群用药的研究进展

综述 | 更新时间：2023-08-15

- 美罗培南药动学/药效学及特殊人群用药的研究进展
- Research progress in pharmacokinetics/pharmacodynamics and drug use of meropenem in special population
- 中国药房 2023年34卷第13期页码：1661-1664
- 作者机构：
  
  1.安徽医科大学第三附属医院药学部，合肥　230061
  2.安徽医科大学药学院，合肥　230061
- 作者简介：
  
  硕士研究生。研究方向：临床药学。电话：0551-62183192。E-mail：m15551656317@163.com
  主任药师，硕士生导师，博士。研究方向：临床药学、药理学。电话：0551-62183936。E-mail：zcandxbf@163.com
- 基金信息：
  
  基金项目安徽医科大学第三附属医院基础与临床合作研究提升计划培育专项(No.2022sfy016)
- DOI：10.6039/j.issn.1001-0408.2023.13.23
  中图分类号： R969.1;R978.1
- 纸质出版日期：2023-07-15，
  
  收稿日期：2022-11-11，
  
  修回日期：2023-03-31，
扫描看全文
徐红艳,黄健,武阿龙等.美罗培南药动学/药效学及特殊人群用药的研究进展 ^Δ[J].中国药房,2023,34(13):1661-1664.

XU Hongyan,HUANG Jian,WU Along,et al.Research progress in pharmacokinetics/pharmacodynamics and drug use of meropenem in special population[J].ZHONGGUO YAOFANG,2023,34(13):1661-1664.
徐红艳,黄健,武阿龙等.美罗培南药动学/药效学及特殊人群用药的研究进展 ^Δ[J].中国药房,2023,34(13):1661-1664. DOI： 10.6039/j.issn.1001-0408.2023.13.23.

XU Hongyan,HUANG Jian,WU Along,et al.Research progress in pharmacokinetics/pharmacodynamics and drug use of meropenem in special population[J].ZHONGGUO YAOFANG,2023,34(13):1661-1664. DOI： 10.6039/j.issn.1001-0408.2023.13.23.

摘要

美罗培南是治疗多药耐药菌感染的首选药物，已广泛应用于临床，但特殊人群的生理病理特征会对美罗培南的药动学/药效学（PK/PD）参数产生影响，临床应用时需根据患者特征制定个体化给药方案。因此，本文总结了美罗培南在特殊人群中的PK/PD特点和应用，推荐美罗培南在儿童患者中给予10～40 mg/kg，q8 h；在老年患者中给予1 g，q8～12 h；在肾功能不全、接受连续静脉-静脉血液滤过和连续静脉-静脉血液透析的患者中给予0.75 g，q8 h；在肾功能亢进患者中给予1 g，q8 h延长输注至3 h或2 g，q8 h；在肝硬化患者中给予2 g负荷剂量后再给予1 g，q8 h。

Abstract

Meropenem is the first choice for the treatment of multi-drug-resistant bacterial infections， which has been widely used in clinical practice. However， the physiological and pathological characteristics of special populations have a significant impact on the pharmacokinetics/pharmacodynamics （PK/PD） parameters of meropenem， so it is necessary to develop individualized drug administration plan according to the characteristics of patients in clinical application. Therefore， this paper summarizes PK/PD characteristics and application of meropenem in special population， and recommends the dosage of meropenem as follows： 10-40 mg/kg， q8 h for children； 1 g， q8-12 h for elderly patients； 0.75 g， q8 h for the patients with renal insufficiency who received continuous veno-venous hemofiltration and continuous veno-venous hemodialysis； 1 g， q8 h prolonged infusion until 3 hours or 2 g， q8 h for patients with hyperrenal function； 1 g， q8 h after 2 g loading dose for patients with cirrhosis.

关键词

美罗培南药动学药效学药物相互作用治疗药物监测

Keywords

pharmacodynamicspharmacokineticsdrug interactiontherapeutic drug monitoring

references

KONG L T，TANG Y，ZHANG X H，et al. Pharmacokinetic/pharmacodynamic analysis of meropenem for the treatment of nosocomial pneumonia in intracerebral he- morrhage patients by Monte Carlo simulation[J]. Ann Pharmacother，2017，51（11）：970-975.

BOONPENG A，JARURATANASIRIKUL S，JULLANGKOON M，et al. Population pharmacokinetics/pharmacodynamics and clinical outcomes of meropenem in critically ill patients[J]. Antimicrob Agents Chemother，2022，66（11）：e0084522.

HENDERSON A，PATERSON D L，CHATFIELD M D，et al. Association between minimum inhibitory concentration，beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study[J]. Clin Infect Dis，2021，73（11）：e3842-e3850.

DUBINSKY S，MALIK P，HAJDUCEK D M，et al. Determining the effects of chronic kidney disease on organic anion transporter1/3 activity through physiologically based pharmacokinetic modeling[J]. Clin Pharmacokinet，2022，61（7）：997-1012.

DUBEY V，DEVNATH K，GUPTA V K，et al. Disulfiram enhances meropenem activity against NDM- and IMP-producing carbapenem-resistant Acinetobacter baumannii infections[J]. J Antimicrob Chemother，2022，77（5）：1313-1323.

GROFT L M，CLAEYS K C，HEIL E L. An evaluation of meropenem/vaborbactam for the treatment of nosocomial pneumonia[J]. Expert Opin Pharmacother，2021，22（3）：265-271.

PAAL M，SCHARF C，DENNINGER A K，et al. Target site pharmacokinetics of meropenem：measurement in human explanted lung tissue by bronchoalveolar lavage，microdialysis，and homogenized lung tissue[J]. Antimicrob Agents Chemother，2021，65（12）：e0156421.

GERMOVSEK E，LUTSAR I，KIPPER K，et al. Plasma and CSF pharmacokinetics of meropenem in neonates and young infants：results from the NeoMero studies[J]. J Antimicrob Chemother，2018，73（7）：1908-1916.

AL-SHAER M H，ALGHAMDI W A，GRAHAM E，et al. Meropenem，cefepime，and piperacillin protein binding in patient samples[J]. Ther Drug Monit，2020，42（1）：129-132.

CONTEJEAN A，JAFFRELOT L，BENABOUD S，et al. A meropenem pharmacokinetics model in patients with haematological malignancies[J]. J Antimicrob Chemother，2020，75（10）：2960-2968.

OSHIMA K，NAKAMURA S，IWANAGA N，et al. Efficacy of high-dose meropenem （six grams per day） in treatment of experimental murine pneumonia induced by meropenem-resistant Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother，2017，61（1）：e02056-e02016.

BENÍTEZ-CANO A，LUQUE S，SORLÍ L，et al. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia：a randomized pharmacokinetic trial[J]. Crit Care，2020，24（1）：55.

HOSMANN A，RITSCHER L，BURGMANN H，et al. Meropenem concentrations in brain tissue of neurointensive care patients exceed CSF levels[J]. J Antimicrob Chemother，2021，76（11）：2914-2922.

OHATA Y，TOMITA Y，SUNAKAWA K，et al. Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis[J]. Int J Antimicrob Agents，2019，54（3）：292-300.

KONIG C，GRENSEMANN J，CZORLICH P，et al. A dosing nomograph for cerebrospinal fluid penetration of meropenem applied by continuous infusion in patients with nosocomial ventriculitis[J/OL]. 2022[2023-03-27]. https：//www.ncbi.nlm.nih.gov/pubmed/35182756https://www.ncbi.nlm.nih.gov/pubmed/35182756. DOI：10.1016/j.cmi.2022.02.017http://dx.doi.org/10.1016/j.cmi.2022.02.017.

MOON Y S，CHUNG K C，GILL M A. Pharmacokinetics of meropenem in animals，healthy volunteers，and patients[J]. Clin Infect Dis，1997，24（Suppl 2）：S249-S255.

IKAWA K，KONDO N，NAKASHIMA A，et al. Penetration of meropenem into human pancreatic juice[J]. Scand J Infect Dis，2013，45（5）：404-406.

GANGULY S，EDGINTON A N，GERHART J G，et al. Physiologically based pharmacokinetic modeling of meropenem in preterm and term infants[J]. Clin Pharmacokinet，2021，60（12）：1591-1604.

RAPP M，URIEN S，FOISSAC F，et al. Population pharmacokinetics of meropenem in critically ill children with different renal functions[J]. Eur J Clin Pharmacol，2020，76（1）：61-71.

中国医药教育协会感染疾病专业委员会. 抗菌药物药代动力学/药效学理论临床应用专家共识[J]. 中华结核和呼吸杂志，2018，41（6）：409-446.

SILVA M A，DIAS G，CARDOSO T. Correlation of estimated creatinine clearance and glomerular filtration rate in very elderly patients and antibiotic prescribing errors：cohort study [J]. Acta Med Port，2021，34（5）：335-341.

HASSANPOUR R，ZIAIE S，KOBARFARD F，et al. Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease[J]. Eur J Clin Pharmacol，2021，77（6）：831-840.

CHAIJAMORN W，RUNGKITWATTANAKUL D，PATTHARACHAYAKUL S，et al. Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy[J]. J Crit Care，2020，60：285-289.

ALMULHIM A S，AL-DAHNEEN B A，ALSOWAIDA Y S. Pharmacists’ knowledge about the impact of augmented renal clearance on antimicrobial dosing in critically ill patients：a cross-sectional study[J]. Infect Dis Ther，2020，9（3）：599-608.

RAZZAZZADEH S，DARAZAM I A，HAJIESMAEILI M，et al. Investigation of pharmacokinetic and clinical outcomes of various meropenem regimens in patients with ventilator-associated pneumonia and augmented renal clearance[J]. Eur J Clin Pharmacol，2022，78（5）：823-829.

LEE D H，KIM H S，PARK S，et al. Population pharmacokinetics of meropenem in critically ill Korean patients and effects of extracorporeal membrane oxygenation[J]. Pharmaceutics，2021，13（11）：1861.

TAMATSUKURI T，OHBAYASHI M，KOHYAMA N，et al. The exploration of population pharmacokinetic model for meropenem in augmented renal clearance and investigation of optimum setting of dose[J]. J Infect Chemother，2018，24（10）：834-840.

SELIG D J，AKERS K S，CHUNG K K，et al. Meropenem pharmacokinetics in critically ill patients with or without burn treated with or without continuous veno-venous haemofiltration[J]. Br J Clin Pharmacol，2022，88（5）：2156-2168.

BASTIDA C，HERNÁNDEZ-TEJERO M，AZIZ F，et al. Meropenem population pharmacokinetics in patients with decompensated cirrhosis and severe infections[J]. J Antimicrob Chemother，2020，75（12）：3619-3624.

GRENSEMANN J，BUSSE D，KÖNIG C，et al. Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis：an observational study[J]. Ann Intensive Care，2020，10（1）：48.

PIANO S，SINGH V，CARACENI P，et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide[J]. Gastroenterology，2019，156（5）：1368-1380.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

酪氨酸激酶抑制剂治疗胃肠间质瘤的药动学和治疗药物监测研究进展

泊沙康唑口服混悬液在HSCT患者中的剂量校正浓度及其影响因素分析

伏立康唑对肺移植患者术后他克莫司血药浓度影响的真实世界研究

比阿培南药动学/药效学和治疗药物监测的研究进展

儿童抗菌药物个体化治疗现状的多中心调查与分析